Blackstone President and COO Jonathan Gray (Patrick T. Fallon/AFP)

Bumble drops after big shareholder Blackstone and founder Wolfe Herd move to sell a huge chunk of the company

Together the sales, which come after disappointing earnings report, account for more than 17% of the company’s shares outstanding.

J. Edward Moreno

8/14/25 9:08AM

Shares of dating app Bumble plunged after big shareholder Blackstone and Bumble founder and CEO Whitney Wolfe Herd filed to sell more than 17% of the company.

Blackstone, which was listed in regulatory filings as several numerical holding companies with the title “BX Buzz” and an address “c/o the Blackstone Group,” registered to sell nearly 16.7 million shares, which would amount to about 16% of Bumble’s shares outstanding. The filings were signed by Robert Brooks, Blackstone’s senior managing director and head of private equity finance. According to the latest FactSet data, Blackstone recently owned more than 27% of the company.

Wolfe Herd, Bumble’s founder who recently returned as CEO, also filed to sell about 1.4 million shares, or $9.7 million worth, at the stock’s closing price. FactSet shows her stake was recently about 2.1 million shares.

Blackstone and Bumble didn’t immediately respond to requests for comment.

Shares of Bumble were down 18% to $5.88 in early trading.

Blackstone sold chunks of its position for about $6.50 a share, significantly less than the $7.15 the stock closed at on Wednesday, the filings show. The dating app, which has struggled to spark sales growth, recently reported a surprise loss for the second quarter of this year.

Toby Bochan, Luke Kawa

Market Wrap

US stocks close at record highs on US-China trade truce optimism

The S&P 500, Nasdaq 100, and Russell 2000 all started off the week with record highs ahead of a big earnings week, with five of the members of the Magnificent 7 reporting.

Max Knoblauch2h

Bullish options flows boost Rivian

EV maker Rivian is up nearly 5% on Monday afternoon as bullish options flows lift the stock ahead of its third-quarter earnings, set to drop next week.

According to Bloomberg, Rivian call options traded outnumber put options more than five to one, for a put/call ratio of less than 0.2 as of 2:38 p.m. ET. That’s significantly less than the 20-day put/call average of 0.4. More than 116,000 call options have changed hands, more than 60% above the full-day average over the past 20 days.

Rivian’s upcoming earnings will measure the automaker’s sales ahead of the expiration of the $7,500 EV tax credit. Since September, Rivian has performed two rounds of layoffs as it seeks to cut costs amid the end of regulatory credits and ahead of next year’s lower-cost SUV launch.

Matt Phillips4h

Palantir inks defense deal with Poland, touches new intraday high

Palantir Technologies touched a new intraday high of $192.83 early Monday, as the company rode the China trade truce rally in AI tech stocks and retail favorites.

Palantir also signed a new deal to supply the government of Poland with data, AI, and cybersecurity software, according to Bloomberg.

Polish Minister of Defense Wladyslaw Kosiniak-Kamysz and Palantir CEO Alex Karp signed the letter of intent on the deal, about which few details were released. Polish officials did signal that they were interested in Palantir software systems for “battlefield management” and logistics. Up more than 150% this year, Palantir reports Q3 earnings on November 3.

Poland Signs Palantir, Anduril Deals Amid Record Army Spending

J. Edward Moreno5h

Intellia tanks as it pauses late-stage CRISPR gene-editing trials after one patient was hospitalized

Intellia dropped sharply on Monday after it announced that it’s pausing two late-stage CRISPR gene-editing trials because one patient was hospitalized with liver damage.

Intellia had also disclosed in May that a patient had experienced elevated liver enzymes. The news is a major setback for the company, which currently has no products on the market and is working on a one-time treatment for heart and nerve conditions.

The news dragged down other companies working on CRISPR treatments, including Beam Therapeutics Inc, Crispr Therapeutics, Editas Medicine, and Prime Medicine.

Luke Kawa5h

Gold craters as retail traders pull money from commodity ETFs

As its fierce rally begins to fade, it looks like retail traders are waving au revoir to gold.

JPMorgan strategist Arun Jain noted that retail traders have pulled about $120 million from commodity ETFs as of 11 a.m. ET on Monday, a level that stands in the 0.4th percentile relative to its one-year average. The SPDR Gold Shares ETF is down 2.8% as of 11:53 a.m. ET after suffering its worst loss since April 2013 last Tuesday. That day, retail had pulled just $50 million from commodity ETFs by 11 a.m.

The five-session average daily flows into the product hit an all-time high of nearly $1.1 billion last Monday as gold and silver had effectively become the new meme stocks, displaying strong momentum and heavy options activity.